STOCK TITAN
  1. Home
  2. News
  3. NURO

NeuroMetrix, Inc. - NURO STOCK NEWS

Welcome to our dedicated page for NeuroMetrix news (Ticker: NURO), a resource for investors and traders seeking the latest updates and insights on NeuroMetrix stock.

NeuroMetrix, Inc., based in Waltham, Massachusetts, is a leading innovator in the healthcare sector, focusing on the development and commercialization of neurotechnology devices. Founded in 1996 as a spinoff from the Harvard-MIT Division of Health Sciences and Technology, the company uniquely combines bioelectrical and digital medicine to address chronic health conditions such as chronic pain, sleep disorders, and diabetes.

The company's flagship product, Quell®, is a wearable neuromodulation platform that offers drug-free pain relief through clinical-grade neurostimulation. Quell® is designed to help individuals suffering from chronic back pain, arthritic pain, nerve pain, and other chronic pain conditions manage their symptoms effectively. Its user-friendly app further aids patients in reclaiming their quality of life.

Another notable product is DPNCheck®, a point-of-care screening test designed for peripheral neuropathy, particularly in diabetic patients. This device has become an essential tool for early diagnosis and management of neuropathy.

NeuroMetrix continues to invest in research and development, maintaining several pipeline programs aimed at expanding their product offerings and improving existing technologies. The company’s current projects include refining their wearable devices to integrate more advanced features, enhancing user experience through mobile apps, and leveraging cloud-based systems for data analysis and management.

Additionally, NeuroMetrix has established significant partnerships and collaborations to expand its market reach and enhance its technological capabilities. Despite the challenges highlighted in recent news, including shareholder concerns about stock valuation and leadership, the company remains focused on delivering innovative healthcare solutions.

For more updates and detailed information on NeuroMetrix's performance, events, and developments, visit NeuroMetrix.com.

News

Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.

Rhea-AI Summary
Echo Lake Capital's Ephraim Fields urges Neurometrix, Inc. to liquidate due to significant undervaluation, questioning the Board's commitment to shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.97%
Tags
none
-
News

NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights

Rhea-AI Summary
NeuroMetrix, Inc. (NURO) reported financial and business highlights for Q4 2023. Quell Fibromyalgia showed accelerated growth with new business development strategies. The company filed for FDA approval for Quell for chemotherapy induced peripheral neuropathy. However, pressure on the DPNCheck market due to changes in CMS regulations poses a challenge.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.26%
Tags
none
-
News

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call

Rhea-AI Summary
NeuroMetrix, Inc. (NURO) will release its 2023 fourth quarter and year-end business and financial highlights on February 22, 2024. The company will conduct a conference call at 8:00 a.m. ET on the same day for participants to ask questions. Access to the call can be obtained by registering in advance. An audio-only webcast and financial statements will be available on the company's website. A replay of the call will also be accessible for one year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.57%
Tags
none
News

NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value

Rhea-AI Summary
NeuroMetrix, Inc. (NURO) announces a strategic review process to enhance growth and shareholder value. The company plans to explore various options, including marketing strategy changes, asset acquisition, asset sale, and strategic transactions. Ladenburg Thalmann & Co. is engaged as the financial advisor. The company aims to leverage opportunities for Quell neuromodulation technology and address Medicare Advantage risk adjustment changes affecting the DPNCheck business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.55%
Tags
none
-
News

NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024

Rhea-AI Summary
NeuroMetrix, Inc. (NURO) to Present at Emerging Growth Conference on January 10, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
conferences acquisition
-
News

NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)

Rhea-AI Summary
NeuroMetrix, Inc. (Nasdaq: NURO) presented data from a clinical trial of Quell wearable neuromodulation technology for Long COVID patients. The trial was conducted at Baylor College of Medicine in collaboration with C2SHIP, with Dr. Bijan Najafi as the principal investigator.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
clinical trial covid-19
News

NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)

Rhea-AI Summary
NeuroMetrix, Inc. (NURO) announced the publication of results from an NIH-funded clinical trial of Quell for chronic chemotherapy-induced peripheral neuropathy (CIPN) in The Journal of Pain. The phase 2 trial showed significant improvement in CIPN-related quality of life, meeting its primary endpoint. Minor adverse events were reported, primarily mild skin irritation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
clinical trial
-
News

NeuroMetrix Announces One-for-Eight Reverse Stock Split

Rhea-AI Summary
NeuroMetrix, Inc. (NASDAQ: NURO) announced a one-for-eight reverse split of its common stock to increase the per share trading price and comply with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The reverse stock split will consolidate every eight shares into one, with no change in nominal par value. No fractional shares will be issued, and shareholders entitled to receive a fractional share will receive a cash payment. Trading on the Nasdaq Capital Market will continue on a split-adjusted basis under the new CUSIP number and symbol 'NURO' on November 22, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023

Rhea-AI Summary
NeuroMetrix, Inc. will present at the Emerging Growth Conference on November 1, 2023. Dr. Shai N. Gozani, Chairman and CEO, will provide an update on business highlights and recent developments, including Quell® neuromodulation technology. The presentation is scheduled for 3:40pm EDT and will last approximately 10 minutes. Registration is required to attend the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.77%
Tags
conferences acquisition
News

NeuroMetrix Reports Q3 2023 Business Highlights

Rhea-AI Summary
NeuroMetrix reports business and financial highlights for Q3 2023. Quell Fibromyalgia shows growth with increased prescriptions and refills. Partnership with National Fibromyalgia Association announced. Clinical trial shows Quell's effectiveness for chemotherapy induced peripheral neuropathy. NASDAQ delisting notice received. Financial results consistent with expectations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.4%
Tags
earnings

FAQ

What is the current stock price of NeuroMetrix (NURO)?

The current stock price of NeuroMetrix (NURO) is $3.95 as of December 23, 2024.

What is the market cap of NeuroMetrix (NURO)?

The market cap of NeuroMetrix (NURO) is approximately 8.0M.

What does NeuroMetrix, Inc. specialize in?

NeuroMetrix specializes in developing neurotechnology devices to address chronic pain, sleep disorders, and diabetes.

What are the main products offered by NeuroMetrix?

The main products are Quell®, a wearable neuromodulation platform, and DPNCheck®, a point-of-care screening test for peripheral neuropathy.

Where is NeuroMetrix located?

NeuroMetrix is located in Waltham, Massachusetts.

When was NeuroMetrix founded?

NeuroMetrix was founded in 1996 as a spinoff from the Harvard-MIT Division of Health Sciences and Technology.

What is Quell® used for?

Quell® is used for drug-free pain relief through clinical-grade neurostimulation, effective for chronic back pain, arthritic pain, nerve pain, and other chronic pain conditions.

What is DPNCheck®?

DPNCheck® is a point-of-care screening test for peripheral neuropathy, which is particularly essential for diabetic patients.

Does NeuroMetrix have any ongoing research projects?

Yes, NeuroMetrix maintains active research efforts and has several pipeline programs aimed at expanding their product offerings and improving existing technologies.

How can I get more information about NeuroMetrix?

For more detailed information, you can visit the company's official website at www.NeuroMetrix.com.

What recent achievements has NeuroMetrix announced?

Recently, NeuroMetrix announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022.

What challenges is NeuroMetrix currently facing?

NeuroMetrix is currently addressing shareholder concerns about stock valuation, leadership decisions, and overall strategic direction.

Stock NURO logo
NeuroMetrix, Inc.

Nasdaq:NURO

NURO Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

NURO Stock Data

7.97M
1.52M
25.45%
3.01%
2.08%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
WALTHAM